How a scientist at Enzene is rethinking manufacturing to make anti-cancer drugs affordable in India

Himanshu Gadgil, CEO, Enzene Biosciences; Enzene Biosciences in Pune; image credit: Enzene


Anti-cancer drugs are beyond the reach of average Indian patients. Early-stage patients spend up to INR6 lakh on medicines alone. For advanced stages, the cost is higher. Scientist Himanshu Gadgil gave up a cushy job in the US and returned to India with a mission. Pioneering a unique manufacturing process, he is changing the game, one drug at a time.

At Amgen’s Thousand Oaks headquarters in California, Himanshu Gadgil had everything that talented young scientists aspire for. In his seven-year stint with the American biotech giant, Gadgil helmed several product-development teams, led interactions with top regulatory agencies, and authored scientific papers. Until fate took a tragic turn. In 2009, Gadgil’s father passed away, having suffered internal bleeding because of dengue. In his final

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *